Should patients with optic neuritis be treated with steroids?

Area of Science:

• Ophthalmology
• Neurology
• Neuroimmunology

Background:

• Optic neuritis is a leading cause of optic neuropathy in young adults.
• High-dose intravenous corticosteroids (IVCS) have been the standard treatment for acute optic neuritis since the Optic Neuritis Treatment Trial (ONTT).
• Ongoing research continues to refine understanding of corticosteroid efficacy and limitations in optic neuritis management.

Purpose of the Study:

• To review current evidence on the efficacy and limitations of corticosteroids for acute optic neuritis.
• To explore recent findings regarding factors influencing IVCS treatment, such as race and administration route.
• To reaffirm the role of IVCS as a primary treatment modality.

Main Methods:

• Review of recent clinical research and studies on optic neuritis treatment.
• Analysis of data concerning the impact of IVCS on visual recovery, final visual outcome, and multiple sclerosis progression.
• Evaluation of treatment recommendations based on patient-specific factors and risks.

Main Results:

• High-dose IVCS accelerate visual recovery in acute typical optic neuritis without affecting the final visual outcome.
• IVCS can delay the progression to clinically definite multiple sclerosis (CDMS) within the first two years.
• The delay in CDMS progression is not observed at five or ten-year follow-ups.

Conclusions:

• High-dose IVCS are effective for hastening visual recovery in acute optic neuritis.
• While IVCS may offer a short-term delay in multiple sclerosis progression, this effect is not durable.
• Treatment with high-dose IVCS is recommended for patients with significant vision loss, pain, or MRI-evident lesions, provided benefits outweigh risks.